# PLEOPHARMA TO PRESENT NEWDATA ON CANNABIS WITHDRAWAL In PATIENTS … > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/pleopharma-to-present-newdata-on-cannabis-withdrawal-in-patients/ > **Published:** 2026-06-16T00:15:00-04:00 | **Last Modified / Clinically Audited:** 2026-09-08T20:23:24-04:00 > **Clinical Summary:** New patient-reported data on cannabis withdrawal severity in use disorder. Clinical guidance for managing withdrawal during cessation. --- ✦ New CED Clinical Relevance #75 Strong Clinical Relevance High-quality evidence with meaningful patient or clinical significance. ResearchMental HealthSafetyNeurologyPolicyPainAnxiety Why This Matters Clinicians managing patients with [cannabis use disorder](https://cedclinic.com/sex-differences-cannabis-stress-reactivity-oxytocin/) need evidence-based approaches to address withdrawal symptoms, which can impede treatment adherence and recovery outcomes. Understanding patient-reported severity and patterns of cannabis withdrawal helps guide appropriate monitoring, symptom management strategies, and realistic treatment timelines for affected patients. This qualitative data may inform clinical decision-making about whether pharmacological or behavioral interventions are warranted to improve treatment success rates in [cannabis use](https://cedclinic.com/cannabis-cardiovascular-health-insights-2024/) disorder. Clinical Summary This qualitative study examined patient-reported outcomes in 15 participants with [cannabis use disorder](https://cedclinic.com/sex-differences-cannabis-stress-reactivity-oxytocin/), focusing on the severity and characteristics of [cannabis withdrawal symptoms](https://cedclinic.com/cannabis-use-disorder-risk-clinical-evidence/). Understanding the withdrawal experience is clinically important because many patients attempting to discontinue cannabis report troublesome symptoms that can undermine treatment success and lead to relapse. The findings from this patient-centered approach provide insights into the subjective burden of withdrawal that standard clinical assessments may miss, including emotional, cognitive, and physical manifestations that matter most to individuals trying to quit. These data are particularly relevant given the increasing potency of modern cannabis products and growing numbers of patients seeking help for [cannabis dependence](https://cedclinic.com/ptsd-cannabis-dependence-veterans-social-support/) in clinical settings. For clinicians managing patients with [cannabis use](https://cedclinic.com/cannabis-cardiovascular-health-insights-2024/) disorder, this research underscores the need to explicitly assess and validate withdrawal symptoms as part of treatment planning and to consider supportive interventions or symptom management strategies during the discontinuation period. Clinicians should routinely discuss expected withdrawal effects with patients to improve treatment adherence and reduce the likelihood of premature discontinuation or relapse. Dr. Caplan’s Take “This is a small qualitative study with 15 participants, so while patient-reported withdrawal experiences are clinically valuable to hear, we need larger controlled trials before we can establish whether any intervention truly modifies withdrawal severity in a reproducible way.” Clinical Perspective 🧠 While cannabis withdrawal syndrome is increasingly recognized as a clinical entity, this small qualitative study of 15 participants presents patient-reported outcomes that, though valuable for understanding subjective experiences, should be interpreted cautiously given the limited sample size, lack of control group, and absence of standardized validated instruments for measuring withdrawal severity. The heterogeneity of [cannabis use](https://cedclinic.com/cannabis-cardiovascular-health-insights-2024/) patterns, potency variations in illicit versus regulated products, and individual differences in [cannabinoid metabolism](https://cedclinic.com/fatty-acid-amide-hydrolase-obesity-risk-genetic-links/) represent significant confounders that qualitative designs may not adequately address. Nevertheless, systematically documenting withdrawal symptoms and severity—including sleep disturbance, irritability, and mood changes—serves an important clinical function in validating patient experiences and improving provider recognition of [cannabis use disorder](https://cedclinic.com/sex-differences-cannabis-stress-reactivity-oxytocin/) as a treatable condition. Practitioners should use findings like these to inform empathetic screening conversations with patients who use cannabis, while recognizing that evidence-based pharmacological interventions for cannabis withdrawal remain limited and that current 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/forum/cannabis-related-research/) Have thoughts on this? Share it: [X Share on X](https://twitter.com/intent/tweet?text=Just%20read%20this%20on%20CEDclinic.com%3A%20PLEOPHARMA%20TO%20PRESENT%20NEWDATA%20ON%20CANNABIS%20WITHDRAWAL%20In%20PATIENTS%20...%20%40drcaplan&url=https%3A%2F%2Fcedclinic.com%2F%3Fp%3D59185)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fcedclinic.com%2F%3Fp%3D59185)[🦅 Share on BlueSky](https://bsky.app/intent/compose?text=Just%20read%20this%3A%20PLEOPHARMA%20TO%20PRESENT%20NEWDATA%20ON%20CANNABIS%20WITHDRAWAL%20In%20PATIENTS%20...%20via%20%40drcaplan.bsky.social%20https%3A%2F%2Fcedclinic.com%2F%3Fp%3D59185)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan)[📝 Read more on Substack](https://doctorapprovedcannabis.substack.com/)[🔔 Subscribe via RSS](https://cedclinic.com/feed/) 📰 Source: [https://finance.yahoo.com/healthcare/articles/pleopharma-present-newdata-cannabis-withdrawal-000700918.html](https://finance.yahoo.com/healthcare/articles/pleopharma-present-newdata-cannabis-withdrawal-000700918.html) Further Reading CED Clinic Blog[Why Cannabis Works](https://cedclinic.com/why-cannabis-works/) Evidence Watch[Cannabis and Heart Health](https://cedclinic.com/cannabis-cardiovascular-health-study/) CED Clinic Blog[Cannabis for Sleep](https://cedclinic.com/cannabis-for-sleep/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).